Ameriprise discloses 8.4% Pasithea Therapeutics (NASDAQ: KTTA) stake
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC filed a Schedule 13G reporting beneficial ownership of 1,930,128 shares of Pasithea Therapeutics Corp. common stock, equal to 8.4% of the class as of 12/31/2025.
Both entities report zero sole voting or dispositive power and shared voting and dispositive power over all reported shares. They state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pasithea Therapeutics.
Positive
- None.
Negative
- None.
FAQ
What stake in Pasithea Therapeutics (KTTA) did Ameriprise report?
Ameriprise Financial and its adviser reported beneficial ownership of 1,930,128 Pasithea Therapeutics common shares, representing 8.4% of the outstanding class as of 12/31/2025. All reported shares are subject to shared, not sole, voting and dispositive power.
Who are the reporting persons in this Pasithea (KTTA) Schedule 13G?
The Schedule 13G lists Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC as reporting persons. Ameriprise is the parent of Columbia, and Ameriprise may be deemed to beneficially own the same 1,930,128 shares reported by Columbia through its advisory relationship.
Is Ameriprise’s Pasithea (KTTA) position a passive investment?
Yes. The certification states the Pasithea securities were acquired and are held in the ordinary course of business, not to change or influence control of the issuer, and not in connection with any transaction intended to affect control, other than limited nomination-related activities allowed by regulation.